Author:
Rodnick Melissa E.,Sollert Carina,Parr D. Christian,Frigell Jens,Gagnon Katherine,Scott Peter J. H.
Reference29 articles.
1. Herrmann K, Schwaiger M, Lewis JS, Solomon SB, McNeil BJ, Baumann M, Gambhir SS, Hricak H, Weissleder R (2020) Radiotheranostics: a roadmap for future development. Lancet Oncol 21:e146–e156
2. Qaim SM, Scholten B, Neumaier B (2018) New developments in the production of theranostic pairs of radionuclides. J Radioanal Nucl Chem 318:1493–1509
3. Pencharz D, Gnanasegaran G, Navalkissoor S (2018) Theranostics in neuroendocrine tumours: somatostatin receptor imaging and therapy. Br J Radiol 91:20180108
4. FDA approves new diagnostic imaging agent to detect rare neuroendocrine tumors. [new release]. https://www.fda.gov/news-events/press-announcements/fda-approves-new-diagnostic-imaging-agent-detect-rare-neuroendocrine-tumors. Published 1 Jun 2016; Accessed 2 Jun 2021
5. Sunderland JJ (2020) The Academic NDA: justification, process, and lessons learned. J Nucl Med 61:480–487
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献